

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

June 24, 2015

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for April 22, 2014 meeting (Tab 1; pages 3-6)
- IV. Secretary's report (Tab 2; pages 7-8)
- V. Old Business (Tab 3; pages 9-14)
 - A. HMO (UHC) response to DURB follow-up questions regarding "directed interventions"
 - B. Summary of Patients on Chronic Opioids Dose with Acute Diagnosis
 - C. Current direct-acting antiviral Hepatitis C drugs by genotype
- VI. New Business
 - A. Paliperidone palmitate (Invega Trinza[®]) proposed protocol (Tab 4; pages 15-16)
 - B. Protocols review (Tab 5; pages 17-26)
 - 1. Novel oral anticoagulants
 - 2. Testosterone products
- VII. Informational Highlights/Reports
 - 1. Molina/NJ HMO 1st Quarter 2015 Prior Authorization Report (Tab 6; pages 27-28)
 - 2. Summary of DURB Action Items (Tab 7; pages 29-30)
 - 3. DHS and DHSS Programs Top Drugs Report (Tab 8; pages 31-50)
 - 4. Medication information: (Tab 9; pages 51-55)
 - (a) Heroin Use Surges Among Whites Who Abuse Prescription Painkillers
 - (b) Injectable Testosterone Tied to Higher MI, Stroke Risk Than Gels
 - (c) FDA approves first 3-month schizophrenia treatment
 - (d) The FDA warns on newer class of type 2 diabetes drugs (SGLT2 inhibitors)